Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Recruiting · NCT07467772 · Registry updated 2026-05-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ph 2 Elacestrant in ER Positive Uterine Sarcomas | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, endometrial stromal tumor, endometrioid stromal sarcoma, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, leiomyosarcoma of the corpus uteri, mixed neoplasm, neoplasm, neoplasm with perivascular epithelioid cell differentiation, sarcoma, uterine corpus adenosarcoma, uterine disorder | Recruiting | Phase 2 | 2026-05-22 | NCT07467772 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| Stemline Therapeutics, Inc. | 22 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 300 |